Americans now have a record share of their financial assets in equities, which raises the stakes for choosing where every new dollar goes. With so much capital already tied to markets, investors are paying closer attention to sectors that can offer essential services through different economic moods. Healthcare fits that bill. This article breaks down three leading healthcare stocks from a curated screener that focuses on financial strength and staying power.
The stocks highlighted below are just a sample from this healthcare idea, and the full screen surfaced 36 more companies with equally compelling stories that are not covered in this article. If you want to quickly identify your own high-conviction candidates across providers, drug developers, equipment makers, and health tech, head straight to the Best Healthcare Stocks screener .
BeOne Medicines (ONC)
BeOne Medicines plugs directly into the Best Healthcare Stocks theme through its marketed cancer treatments, giving you a large cap pure-play on commercial oncology alongside a crowded but well funded pipeline that aims to turn more early science into real world therapies.
BeOne Medicines generates about US$6.1b from pharmaceutical products, reflecting a broad oncology franchise built around commercial drugs, and the stock carries a market value of roughly US$43.5b.
"The chemo free BRUKINSA plus rituximab regimen in the Phase 3 MANGROVE study, which reduced progression or death risk by 43% versus bendamustine plus rituximab and is heading toward filings in the second half of 2026, can reposition BeOne Medicines more toward continuous, higher value frontline B cell malignancy care that supports longer duration revenue per patient."
What ultimately matters is how one still overlooked pressure on BeOne Medicines' oncology engine shapes margins and long term earnings power.
That pressure point is exactly where the story gets interesting, and the full narrative for BeOne Medicines explains how that margin squeeze could potentially translate into accelerating value for long term holders.
TG Therapeutics (TGTX)
TG Therapeutics gives this healthcare screen direct exposure to a marketed multiple sclerosis therapy and a focused group of B cell targeted drug candidates. Together, these elements position the business at the intersection of specialty neurology care and higher quality biotech earnings profiles.
TG Therapeutics focuses on B cell mediated diseases through BRIUMVI for relapsing multiple sclerosis and a related antibody pipeline, generating about US$799 million from biotechnology activities, with a market value near US$7.5b.
TG Therapeutics taps straight into the Best Healthcare Stocks theme through BRIUMVI's role in treating relapsing multiple sclerosis. Its broader antibody and small molecule work adds depth to the story and puts investors close to a targeted corner of neurology care.
"The investigation into potential self dealing by certain TG Therapeutics officers and directors introduces a governance overhang that could lead to legal expenses, management distraction, and reputational damage with physicians and payers."
What happens if a single cost and control assumption in that multiple sclerosis franchise shifts will likely matter more than any headline.
If that assumption is wrong, the full narrative for TG Therapeutics shows how governance risk, BRIUMVI momentum, and pipeline execution could be decoupling headline noise from long term outcomes.
Kiniksa Pharmaceuticals International (KNSA)
Kiniksa Pharmaceuticals International is a biopharma player in the Best Healthcare Stocks theme, built around ARCALYST for recurrent pericarditis and cardiac sarcoidosis and supported by immunology assets KPL-387 and KPL-116, generating about US$840 million from therapeutic medicines with a roughly US$6 billion market cap.
Kiniksa Pharmaceuticals International gives this healthcare screen a pure play cardiovascular and autoinflammatory angle, with ARCALYST anchoring a growing IL‑1 franchise and a focused pipeline suggesting additional potential use cases if the science continues to support them.
"Significant expansion opportunities for ARCALYST remain, as market penetration into the recurrent pericarditis population is still only 15%, with a large additional segment (first recurrence patients) representing another untapped 26,000 patients."
What may significantly influence results for Kiniksa Pharmaceuticals International from here is how one underappreciated shift in treatment habits filters through to margins and earnings power.
That shift in prescribing habits is exactly where the full narrative for Kiniksa Pharmaceuticals International shows whether Kiniksa Pharmaceuticals International has an accelerating, underappreciated earnings engine hiding in plain sight.
Seeking Alternatives Before Momentum Flies
Fresh breakout candidates do not stay under the radar for long. Spot shares that are building momentum while it matters, before the crowd gets caught chasing. Act now.
-
Spot early movers in under‑followed sectors and use the 21 high quality undiscovered gems to find businesses that screens flag as financially strong yet still under the radar.
-
Track cash rich operators as markets swing and let the list of solid balance sheet and fundamentals (25 results) guide you toward balance sheets and fundamentals built to handle pressure.
-
Ride structural infrastructure trends before they are fully priced and scan the 42 power grid technology and infrastructure stocks for companies wired into long term grid upgrades.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
